The much anticipated Local Coverage Determination (LCD) decision has been made in the past 24 hours; Consistent with the proposal, PEB’s Cxbladder tests at this stage will not be covered by CMS on the basis that PEB’s current body of evidence isn’t sufficient to be “considered medically reasonable and necessary”.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.